Tozasertib (VX-680, MK-0457)

Catalog No.S1048

Molecular Weight(MW): 464.59

Tozasertib (VX-680, MK-0457) is a pan-Aurora inhibitor, mostly against Aurora A with K_i_app of 0.6 nM in a cell-free assay, less potent towards Aurora B/Aurora C and 100-fold more selective for Aurora A than 55 other kinases. Phase 2.

Cited by 67 Publications

Nature, 2018, 559(7713):211-216

PubMed: 29973724 ( click the link to review the publication )

Cancer Cell, 2014, 26(3):414-427

PubMed: 25175806 ( click the link to review the publication )

Cell Stem Cell, 2012, 11(2):179-94

PubMed: 22862944 ( click the link to review the publication )

Cell, 2010, 142(3):444-55

PubMed: 20691903 ( click the link to review the publication )

Cancer Res, 2019, 79(1):209-219

PubMed: 30389701 ( click the link to review the publication )

Cancers (Basel), 2019, 11(10)

PubMed: 31652588 ( click the link to review the publication )

Cell Death Dis, 2019, 10(6):385

PubMed: 31097686 ( click the link to review the publication )

Cell Death Dis, 2019, 10(6):432

PubMed: 31160567 ( click the link to review the publication )

FEBS J, 2019, 286(5):963-974

PubMed: 30600590 ( click the link to review the publication )

Antiviral Res, 2019, 170:104572

PubMed: 31376425 ( click the link to review the publication )

Toxicol Sci, 2019, 10.1093/toxsci/kfz123

PubMed: 31132080 ( click the link to review the publication )

J Pharm Biomed Anal, 2019, doi: 101016/jjpba2019112962

PubMed: 31711864 ( click the link to review the publication )

Environ Mol Mutagen, 2019, 60(6):513-533

PubMed: 30702769 ( click the link to review the publication )

Int J Mol Sci, 2018, 19(12)

PubMed: 30544932 ( click the link to review the publication )

Anticancer Drugs, 2018, 29(10):1004-1010

PubMed: 30080692 ( click the link to review the publication )

Neuron, 2017, 94(6):1142-1154

PubMed: 28641113 ( click the link to review the publication )

Toxicol Sci, 2017, 162(1):146-166

PubMed: 29106658 ( click the link to review the publication )

J Biol Chem, 2017, 292(36):15028-15038

PubMed: 28739871 ( click the link to review the publication )

Cell Signal, 2017, 39:74-83

PubMed: 28780319 ( click the link to review the publication )

Nat Chem Biol, 2016, 10.1038/nchembio.2017

PubMed: 26829474 ( click the link to review the publication )

Nat Commun, 2016, 7:10180

PubMed: 26782714 ( click the link to review the publication )

EMBO J, 2016, 35(8):803-19

PubMed: 26929011 ( click the link to review the publication )

Proc Natl Acad Sci U S A, 2016, 113(50):14366-14371

PubMed: 28182563 ( click the link to review the publication )

Arch Toxicol, 2016, 291(10):4939-54

PubMed: 26404763 ( click the link to review the publication )
J Biol Chem, 2016, 10.1074/jbc.M116.722751

PubMed: 27226586 ( click the link to review the publication )

Exp Cell Res, 2016, 344(2):153-66

PubMed: 27138904 ( click the link to review the publication )

Cell Cycle, 2016, 15(15):2009-18

PubMed: 27249336 ( click the link to review the publication )

Oncol Rep, 2016, 36(2):819-26

PubMed: 27373675 ( click the link to review the publication )

Biochem Biophys Res Commun, 2016, 473(1):212-8

PubMed: 27003257 ( click the link to review the publication )

Exp Hematol, 2016, 44(3):189-93

PubMed: 26706195 ( click the link to review the publication )

Tumour Biol, 2016, 37(11):14745-14755

PubMed: 27629142 ( click the link to review the publication )

Nat Cell Biol, 2015, 17(1):31-43

PubMed: 25503564 ( click the link to review the publication )

Nat Commun, 2015, 6:7935

PubMed: 26228240 ( click the link to review the publication )

Clin Cancer Res, 2015, 21(23):5338-48

PubMed: 26152738 ( click the link to review the publication )

Oncol Rep, 2015, 34(2):803-10

PubMed: 26044736 ( click the link to review the publication )

PLoS One, 2015, 10(7):e0134306

PubMed: 26218638 ( click the link to review the publication )

BMC Res Notes, 2015, 8:484

PubMed: 26415506 ( click the link to review the publication )

J Mol Cell Biol, 2014, 6(3):240-54

PubMed: 24847103 ( click the link to review the publication )

Biochim Biophys Acta, 2014, 1843(5):934-44

PubMed: 24480460 ( click the link to review the publication )

Hum Gene Ther, 2014, 25(7):599-608

PubMed: 24568341 ( click the link to review the publication )

Am J Physiol Lung Cell Mol Physiol, 2014, 307(2):L173-85

PubMed: 24838752 ( click the link to review the publication )

PLoS One, 2014, 9(9):e108758

PubMed: 25268132 ( click the link to review the publication )

PLoS One, 2014, 9(7):e102741

PubMed: 25048812 ( click the link to review the publication )

Oncol Lett, 2014, 7(1):121-124

PubMed: 24348832 ( click the link to review the publication )

Oncotarget, 2014, 5(17):7498-511

PubMed: 25115395 ( click the link to review the publication )

Cancer Res, 2013, 73(22):6722-33

PubMed: 24101154 ( click the link to review the publication )

Cancer Res, 2013, 73(20):6310-22

PubMed: 24067506 ( click the link to review the publication )

Mol Cancer Res, 2013, 12(3):433-9

PubMed: 24336958 ( click the link to review the publication )
J Cell Sci, 2013, 126(Pt 5):1235-46

PubMed: 23321637 ( click the link to review the publication )

J Cell Mol Med, 2013, 17(2):265-76

PubMed: 23301855 ( click the link to review the publication )

Vet Comp Oncol, 2013, 10.1111/vco.12018

PubMed: 23410058 ( click the link to review the publication )

Eur J Cancer, 2012, 48(15):2417-30

PubMed: 22244830 ( click the link to review the publication )

Oncogene, 2012, 31(31):3584-96

PubMed: 22120720 ( click the link to review the publication )

J Med Chem, 2012, 55(17):7392-416

PubMed: 22803810 ( click the link to review the publication )

Brain Pathol, 2012, 23(3):244-53

PubMed: 22971244 ( click the link to review the publication )

J Neurosci, 2012, 32(32):11050-66

PubMed: 22875938 ( click the link to review the publication )

Biochem Pharmacol, 2012, 83(9):1217-28

PubMed: 22306067 ( click the link to review the publication )

Biochem J, 2012, 447(1):93-102

PubMed: 22784093 ( click the link to review the publication )

Exp Cell Res, 2012, 318(4):336-49

PubMed: 22197704 ( click the link to review the publication )

Cytoskeleton, 2012, 69(10):840-53

PubMed: 22887753 ( click the link to review the publication )

J Biomol Screen, 2012, 18(4):388-99

PubMed: 23134735 ( click the link to review the publication )

Pediatr Surg Int, 2012, 28(6):579-89

PubMed: 22526548 ( click the link to review the publication )

Curr Biol, 2011, 21(16):1356-65

PubMed: 21820309 ( click the link to review the publication )

Cancer Res, 2011, 71(23):7207-15

PubMed: 21978935 ( click the link to review the publication )

J Biol Chem, 2011, 286(42):36304-15

PubMed: 21878642 ( click the link to review the publication )

Biochem J, 2011, 440(1):85-93

PubMed: 21774789 ( click the link to review the publication )

Mol Cancer Ther, 2010, 9(5):1318-27

PubMed: 20388735 ( click the link to review the publication )

Purity & Quality Control

Choose Selective Aurora Kinase Inhibitors

Biological Activity

Description

Targets

Aurora A ^[1] (Cell-free assay)	Aurora C ^[1] (Cell-free assay)	Aurora B ^[1] (Cell-free assay)	FLT3 ^[4] (Cell-free assay)	Bcr-Abl ^[4] (Cell-free assay)
0.6 nM(Ki app)	4.6 nM(Ki app)	18 nM(Ki app)	30 nM(Ki)	30 nM(Ki)

In vitro

Although its multi-kinase profile, VX-680 induces similar cytotoxicity with IC50 of approximately 300 nM and exhibits an AUR B-like inhibitory phenotype of G2/M arrest, endoreduplication and apoptosis in BaF3 cells transfected with ABL or FLT-3 (mutant and wild type) kinases. VX-680 prevents the CAL-62 proliferation in a time-dependent manner. VX-680 treatment for 14 days significantly decreases the number and size of colonies by approximately 70% in the 8305C and 90% in the CAL-62, 8505C and BHT-101. Treatment of the different ATC cells with VX-680 inhibits proliferation with the IC50 between 25 and 150 nM. The VX-680 significantly impairs the ability of the different cell lines to form colonies in soft agar. Analysis of caspase-3 activity indicates that VX-680 induces apoptosis in the different cell lines. CAL-62 cells exposed for 12 hours to VX-680 showed an accumulation of cells with ≥4N DNA content. Time-lapse analysis demonstrates that VX-680-treated CAL-62 cells exit metaphase without dividing. Moreover, histone H3 phosphorylation is abrogated following VX-680 treatment. ^[2] VX-680 has significant inhibitory activity against BCR-Abl bearing the T315I mutation in patient-derived samples. ^[3]

Cell Data

Cell Lines	Assay Type	Activity Description	PMID
BE-13	NVzudHdET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVnJR\|UxRTBwMECzN\|gh\|ryP	NUfrdZJYW0GQR2LFVi=>
RS4-11	NI\IWVBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXzJR\|UxRTBwMEC0NFQh\|ryP	MmfSV2FPT1KHUh?=
MFH-ino	NYPtWVV6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NG\hcY1KSzVyPUCuNFA6QSEQvF2=	NGj5NZZUSU6JUlXS
NTERA-S-cl-D1	MmXZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXTZdll6UUN3ME2wMlAyPDN2IN88US=>	M3TLc3NCVkeURWK=
697	M4G5Vmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MV7JR\|UxRTBwMEK0O\|Eh\|ryP	MUDTRW5IWkWU
NALM-6	NETWbIlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MUXJR\|UxRTBwMEK1OVIh\|ryP	MWrTRW5IWkWU
ES8	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4XnTGlEPTB;MD6wOFYyOyEQvF2=	M4LZfXNCVkeURWK=
HUTU-80	NHq5NFRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXjLbHp6UUN3ME2wMlA2Ojl7IN88US=>	M3zLcHNCVkeURWK=
MV-4-11	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MUTJR\|UxRTBwMEe3PFIh\|ryP	M13tbHNCVkeURWK=
MONO-MAC-6	NE\RNYVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NEKxPXdKSzVyPUCuNFc5PzlizszN	MnfIV2FPT1KHUh?=
LC-2-ad	NFTQWm9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NID2UYJKSzVyPUCuNFg4QDlizszN	MYXTRW5IWkWU
BL-41	M1GwZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NEn4R2dKSzVyPUCuNVA1PDVizszN	MmX6V2FPT1KHUh?=
A4-Fuk	MmnJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{\pNWlEPTB;MD6xNVU3OyEQvF2=	M1;MTnNCVkeURWK=
SW954	M1rzPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M{LnVWlEPTB;MD6xNlIzQSEQvF2=	M3rkS3NCVkeURWK=
BV-173	Ml6zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1\oNWlEPTB;MD6xNlY1OSEQvF2=	NETLTotUSU6JUlXS
TE-11	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXTDflNqUUN3ME2wMlE1QTh{IN88US=>	NHPrNVlUSU6JUlXS
SK-UT-1	NWLsPXBsT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{nyfGlEPTB;MD6xOVk3PSEQvF2=	MXrTRW5IWkWU
SIG-M5	NX7pOoFRT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnvDTWM2OD1yLkG2O\|A4KM7:TR?=	NG\Re4VUSU6JUlXS
OCUB-M	NXvHUVg1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mmn1TWM2OD1yLkG2PVg{KM7:TR?=	NW\hUodIW0GQR2LFVi=>
K052	M2OxWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFvTSmZKSzVyPUCuNVk1QCEQvF2=	MYDTRW5IWkWU
VA-ES-BJ	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MWrJR\|UxRTBwMkCwPFYh\|ryP	MVTTRW5IWkWU
SW982	NHS2eY5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NUmzSVhDUUN3ME2wMlIyOzhizszN	M3nwSXNCVkeURWK=
LB647-SCLC	MmTGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NUPKfWJ7UUN3ME2wMlIyPTJ\|IN88US=>	NX;5WXIxW0GQR2LFVi=>
PSN1	M3HGXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MnjBTWM2OD1yLkKyNFI3KM7:TR?=	MXvTRW5IWkWU
BB30-HNC	NY\qbFYzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYnaNYNNUUN3ME2wMlIzPTlzIN88US=>	NFLoUGVUSU6JUlXS
ST486	M1jR[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NF;jZ3BKSzVyPUCuNlMxQDdizszN	MVTTRW5IWkWU
MOLT-4	MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYHHe\|BUUUN3ME2wMlI{OzN5IN88US=>	MX7TRW5IWkWU
EW-16	MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Ml;BTWM2OD1yLkKzO\|Y5KM7:TR?=	NUnZNIdkW0GQR2LFVi=>
KS-1	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVHJR\|UxRTBwMkO3PFUh\|ryP	MWPTRW5IWkWU
SR	M1TB[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MmfhTWM2OD1yLkK0OVY1KM7:TR?=	NH:2eolUSU6JUlXS
KM12	MkLhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVLXWnhVUUN3ME2wMlI3OzZizszN	MkfkV2FPT1KHUh?=
EM-2	MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{TkZWlEPTB;MD6yOlY1OSEQvF2=	M2G1U3NCVkeURWK=
MEG-01	MoD2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFr4emVKSzVyPUCuNlc5PDlizszN	MV\TRW5IWkWU
NB13	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NG[xOWRKSzVyPUCuNlc6QDRizszN	NVLSZ2Q2W0GQR2LFVi=>
RKO	NV3oOYZFT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYTJR\|UxRTBwM{C4NVMh\|ryP	NYHIeHNPW0GQR2LFVi=>
CESS	MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MY\JR\|UxRTBwM{GzNlgh\|ryP	MmDqV2FPT1KHUh?=
EoL-1-cell	NW\GTYhoT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFH4ZZdKSzVyPUCuN\|M1PTlizszN	M1nwVXNCVkeURWK=
DOHH-2	M1iwb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXizW4VWUUN3ME2wMlM{PzhzIN88US=>	M3PGXnNCVkeURWK=
A388	NYHSZmlPT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHn0W5lKSzVyPUCuN\|QxQDZizszN	NW\Me\|dRW0GQR2LFVi=>
LAMA-84	NX\5Xm5yT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MmHTTWM2OD1yLkO1NVc5KM7:TR?=	NV3KW\|g5W0GQR2LFVi=>
IMR-5	MmjJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NWLmdXJSUUN3ME2wMlM2PTRizszN	MYDTRW5IWkWU
KARPAS-422	NHPvR4FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXrJR\|UxRTBwM{eyO\|Ih\|ryP	MX7TRW5IWkWU
MRK-nu-1	NWPCeIxMT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MoX2TWM2OD1yLkO4NVMh\|ryP	NIm4NJpUSU6JUlXS
BL-70	MkfPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MonQTWM2OD1yLkO4PVc1KM7:TR?=	NVyy[GlRW0GQR2LFVi=>
LXF-289	Ml;NS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NETTZYZKSzVyPUCuOFA1ODZizszN	MVnTRW5IWkWU
RL95-2	M2HFcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVX5WpFiUUN3ME2wMlQxPTZ5IN88US=>	M3zrT3NCVkeURWK=
QIMR-WIL	NXHkZ\|V3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MX;JR\|UxRTBwNEK2O\|Yh\|ryP	NGXYRmlUSU6JUlXS
K-562	MnyxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Ml3GTWM2OD1yLkSzOFczKM7:TR?=	MoXNV2FPT1KHUh?=
NCI-H510A	NFLRXolIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MU\JR\|UxRTBwNEO4NlMh\|ryP	NYO2dIptW0GQR2LFVi=>
NCI-H524	NYDITWFUT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NGLLWXRKSzVyPUCuOVEyPDdizszN	NIrwZWdUSU6JUlXS
KE-37	MoG2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Ml7QTWM2OD1yLkWyNVAzKM7:TR?=	M{DvTnNCVkeURWK=
KP-N-YS	NWCwTIRCT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWDjUHUxUUN3ME2wMlU1Ozl{IN88US=>	NU\USmxHW0GQR2LFVi=>
LS-411N	NHzkdHBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2rGZWlEPTB;MD61O\|c2OiEQvF2=	NFrrcY5USU6JUlXS
CTV-1	MkDKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3XzU2lEPTB;MD61PFc4OyEQvF2=	MXHTRW5IWkWU
NCI-SNU-16	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MlfXTWM2OD1yLk[zOVcyKM7:TR?=	M1XqfXNCVkeURWK=
HT-144	M1n5XWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3TCfWlEPTB;MD62N\|c6QCEQvF2=	NEPNWmhUSU6JUlXS
NCI-H187	NXG1O5Y{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4[1N2lEPTB;MD62OFE{KM7:TR?=	Mo\lV2FPT1KHUh?=
OCI-AML2	MnLnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWDJR\|UxRTBwNkS0NFMh\|ryP	MVrTRW5IWkWU
CCRF-CEM	NHH3[ndIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWTJR\|UxRTBwNkWzOFYh\|ryP	MWrTRW5IWkWU
ONS-76	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MoTvTWM2OD1yLk[2OFU5KM7:TR?=	MofDV2FPT1KHUh?=
IST-SL2	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{j1eGlEPTB;MD63NVk5OiEQvF2=	MmHOV2FPT1KHUh?=
NB6	NF7UfIxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MmT6TWM2OD1yLke3NlU1KM7:TR?=	NIO3OIZUSU6JUlXS
SK-PN-DW	NETEPIdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVjJR\|UxRTBwN{mxOEDPxE1?	NYXwRmJbW0GQR2LFVi=>
HCC1599	NXTQOpR6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVT4S\|JTUUN3ME2wMlgxQDd2IN88US=>	NWnJTlk6W0GQR2LFVi=>
MC116	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NWfhW4RNUUN3ME2wMlg2ODFzIN88US=>	MV\TRW5IWkWU
TE-15	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MoLzTWM2OD1yLki1NFk5KM7:TR?=	NUHIW5pVW0GQR2LFVi=>
HOP-62	NVnSbpFJT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVfJR\|UxRTBwOE[zNlkh\|ryP	MWfTRW5IWkWU
TGBC24TKB	M{K2Vmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1iwfWlEPTB;MD64OlM5PSEQvF2=	MYHTRW5IWkWU
HCE-4	MmWyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVHJR\|UxRTBwOEiwOlMh\|ryP	NUnydJBkW0GQR2LFVi=>
ALL-PO	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mm\FTWM2OD1yLki4NVc2KM7:TR?=	M4n1dXNCVkeURWK=
KGN	MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYToUY95UUN3ME2wMlg6QTl3IN88US=>	MnrYV2FPT1KHUh?=
ML-2	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MWDJR\|UxRTBwOUCyOVkh\|ryP	MV3TRW5IWkWU
ES4	M2Dwd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYHwV3RiUUN3ME2wMlkyOTJ6IN88US=>	MYfTRW5IWkWU
SF126	M3H1bWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Moi0TWM2OD1yLkm0PFE6KM7:TR?=	M{fiVHNCVkeURWK=
SK-N-DZ	M3zwcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MoXiTWM2OD1yLkm2NVg6KM7:TR?=	MWTTRW5IWkWU
HCC1187	NFXUeGxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4rNOWlEPTB;MT6wNFUxPSEQvF2=	NEPqTlRUSU6JUlXS
DU-4475	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGfEOmJKSzVyPUGuNFE4PTZizszN	M{C5THNCVkeURWK=
NKM-1	Moi0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYXJR\|UxRTFwMEK3O\|Uh\|ryP	MX;TRW5IWkWU
HL-60	NWDzbldiT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4XBdGlEPTB;MT6wOlU4PCEQvF2=	NWPQ[482W0GQR2LFVi=>
SBC-1	NHz2ZoJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHTM[m1KSzVyPUGuNVI2PDJizszN	Mn;BV2FPT1KHUh?=
TE-10	NEPJZVlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWXJR\|UxRTFwMUK5OFYh\|ryP	MXLTRW5IWkWU
ETK-1	M4\I[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1KzfGlEPTB;MT6xN\|YyOyEQvF2=	Mlq5V2FPT1KHUh?=
HAL-01	MoTiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVPJR\|UxRTFwMU[3NFkh\|ryP	NGP3O5hUSU6JUlXS
BB65-RCC	NEi2elVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVTJR\|UxRTFwMUiwNFUh\|ryP	NWXKOVFCW0GQR2LFVi=>
EW-1	Mn;yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MlXhTWM2OD1zLkG4OVYzKM7:TR?=	NXfLSmF5W0GQR2LFVi=>
SK-NEP-1	M2XZPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MUDJR\|UxRTFwMkGxNVEh\|ryP	MV;TRW5IWkWU
SK-LMS-1	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2\lfWlEPTB;MT6yNlIyOiEQvF2=	NUHpemI4W0GQR2LFVi=>
DEL	NFG3RYFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NH7QXXlKSzVyPUGuNlU3PDNizszN	M1rWUHNCVkeURWK=
GT3TKB	NVz0cHRnT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MlTDTWM2OD1zLkK4NFU4KM7:TR?=	M2X5SHNCVkeURWK=
MOLT-16	NGmwUXlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Ml;5TWM2OD1zLkO1OFA2KM7:TR?=	MUPTRW5IWkWU
CMK	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYPpVGM6UUN3ME2xMlQzOTF5IN88US=>	M2niNnNCVkeURWK=
NB5	NEjIWIFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MX;JR\|UxRTFwNkSyNlkh\|ryP	MnTmV2FPT1KHUh?=
NCI-H1963	NIfT[XFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MX\JR\|UxRTFwN{C1PFMh\|ryP	NFq5R\|lUSU6JUlXS
KURAMOCHI	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MlznTWM2OD1zLke4PVEyKM7:TR?=	MVPTRW5IWkWU
TE-8	M4PCdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MlH4TWM2OD1zLkiwN\|Y5KM7:TR?=	NV\reXBjW0GQR2LFVi=>
NCI-H1304	NYf5U291T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVLJR\|UxRTFwOEOwO\|Mh\|ryP	NVTPO3M2W0GQR2LFVi=>
A101D	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NULYcmR3UUN3ME2xMlg4Ozl3IN88US=>	MWjTRW5IWkWU
SCLC-21H	MoruS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NWXQSYQ2UUN3ME2xMlk4ODV5IN88US=>	NV2xS3pNW0GQR2LFVi=>
GB-1	NFXGR2tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3jRVmlEPTB;Mj6wNVY1PyEQvF2=	NX2zNXdHW0GQR2LFVi=>
KARPAS-45	NH\HSFRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NF\ZbJRKSzVyPUKuNFI3PTRizszN	M4DHNHNCVkeURWK=
ATN-1	NH\m[4NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MnjzTWM2OD1{LkCyPFU5KM7:TR?=	NX3tcowyW0GQR2LFVi=>
NCI-H720	NEDIPGxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYPJR\|UxRTJwME[yOFQh\|ryP	NUXHTYVXW0GQR2LFVi=>
RPMI-6666	MkLWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnfSTWM2OD1{LkG2NlA4KM7:TR?=	MoXPV2FPT1KHUh?=
NB17	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MkDRTWM2OD1{LkK5Nlch\|ryP	MlzLV2FPT1KHUh?=
IST-SL1	NFvKR4hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVrJR\|UxRTJwMkm3OlUh\|ryP	NYjHVHd6W0GQR2LFVi=>
SH-4	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGDRPGhKSzVyPUKuN\|I1PjlizszN	MXnTRW5IWkWU
K5	NUTqN3VMT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFTNb4pKSzVyPUKuOFA{OTlizszN	NW[3dIhnW0GQR2LFVi=>
OVCAR-4	MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NH7MOYtKSzVyPUKuOFYyOyEQvF2=	M4TIc3NCVkeURWK=
ACN	NFTXVZlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MoT6TWM2OD1{LkWwNlE{KM7:TR?=	MkDyV2FPT1KHUh?=
TGW	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NUGzU\|JpUUN3ME2yMlY2QDN{IN88US=>	NYSwNIpbW0GQR2LFVi=>
NCI-H2107	NGXXVIJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3rW[2lEPTB;Mj64N\|cyOSEQvF2=	NF:ybVJUSU6JUlXS
NCI-H82	NG[2eWpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFj5ZXlKSzVyPUKuPFM5OzhizszN	NUH2bWY1W0GQR2LFVi=>
SK-N-FI	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXPpc2lIUUN3ME2yMlg3QDZ6IN88US=>	M1XwTXNCVkeURWK=
LB1047-RCC	NYDYfXdFT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NUPuOnRlUUN3ME2yMlg5OTJ4IN88US=>	NXm5V4diW0GQR2LFVi=>
LU-134-A	MmrSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnSyTWM2OD1{Lki5NlYh\|ryP	NVTvRVRzW0GQR2LFVi=>
NCI-H209	NXnx[mRyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3HUdWlEPTB;Mj65NVI2OyEQvF2=	NWDF[lFnW0GQR2LFVi=>
NOMO-1	NYO0XW1IT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MkXNTWM2OD1\|LkCyNlc1KM7:TR?=	NHnIfY9USU6JUlXS
RH-1	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MWnJR\|UxRTNwMUeyPVEh\|ryP	M37ZRnNCVkeURWK=
LOUCY	MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{HqR2lEPTB;Mz6xPFY6OyEQvF2=	MkLuV2FPT1KHUh?=
TE-9	MoLNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYjJR\|UxRTNwMk[3N\|Yh\|ryP	NUf4e4xEW0GQR2LFVi=>
PF-382	NIjuR4RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2fYWWlEPTB;Mz6zOVc4QCEQvF2=	NHTpdG9USU6JUlXS
RPMI-8402	NFfodWNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHrqSlVKSzVyPUOuOVg3ODNizszN	M2C1cXNCVkeURWK=
HEL	MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NIXLZXRKSzVyPUOuOlMzKM7:TR?=	MXTTRW5IWkWU
NOS-1	NX3E[4IyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHLMXpZKSzVyPUOuPFQ4PTRizszN	Ml\BV2FPT1KHUh?=
ES1	NXqzPItjT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MkX6TWM2OD1\|LkmyNlk{KM7:TR?=	M3zsb3NCVkeURWK=
NCI-H2171	NX3Nc4lHT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVLBZmNZUUN3ME2zMlkzPDJ\|IN88US=>	MYnTRW5IWkWU
NCI-H747	NV7RVFIzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3;Xe2lEPTB;Mz65OFIzOSEQvF2=	NXvBcZpqW0GQR2LFVi=>
MHH-NB-11	NVXUfY9VT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NV71Z4gzUUN3ME2zMlk2OzF{IN88US=>	MlHQV2FPT1KHUh?=
MZ1-PC	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1noVWlEPTB;Mz65PVI1KM7:TR?=	M2nLR3NCVkeURWK=
MMAC-SF	MoXmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4jiSWlEPTB;ND6wNlQ3PyEQvF2=	MlTvV2FPT1KHUh?=
NMC-G1	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MX;JR\|UxRTRwMkK3NlMh\|ryP	M2PzV3NCVkeURWK=
SW872	M3\OU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MUXJR\|UxRTRwM{SzOEDPxE1?	MVvTRW5IWkWU
TE-12	NXr3S2RXT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MmjiTWM2OD12LkW2N\|k1KM7:TR?=	MmLSV2FPT1KHUh?=
LU-139	MlLkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MoLETWM2OD12Lk[xPFM2KM7:TR?=	M2PXN3NCVkeURWK=
HC-1	NGD6ZmVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NWnGR5dKUUN3ME20MlY6PDl2IN88US=>	M4[yVHNCVkeURWK=
COR-L279	NYm2WWhST3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MorNTWM2OD12Lke1PFkyKM7:TR?=	M2mzWnNCVkeURWK=
SF268	M2HEXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mm\TTWM2OD12Lke5PVE3KM7:TR?=	MWHTRW5IWkWU
MC-CAR	NUDPbWFKT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MUHJR\|UxRTVwME[3OVch\|ryP	MYDTRW5IWkWU
TK10	M13Ucmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NV7nVFF1UUN3ME21MlM2PDZ7IN88US=>	M1fIW3NCVkeURWK=
TE-1	NE\tN4xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHXaOY1KSzVyPUWuOFkxODRizszN	MnHBV2FPT1KHUh?=
NCI-H2126	M1q5[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MojpTWM2OD13Lk[0OVc1KM7:TR?=	NXTxd5lsW0GQR2LFVi=>
Daudi	M3W4c2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHW2OIVKSzVyPUWuOlkyOiEQvF2=	NFi5N2xUSU6JUlXS
NCI-H1648	NYLocWE6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1rWRWlEPTB;NT64NVQ2PCEQvF2=	MWDTRW5IWkWU
OS-RC-2	MkjHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NIOyR3FKSzVyPUWuPVg2QTdizszN	MXzTRW5IWkWU
DJM-1	MnPlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVHJR\|UxRTZwM{S2OlYh\|ryP	NW\KXopVW0GQR2LFVi=>
LS-1034	M4LuUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M{nnZ2lEPTB;Nj63OVY3KM7:TR?=	MV\TRW5IWkWU
NCI-H1581	MmPIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MmDxTWM2OD14Lke4OFA2KM7:TR?=	NEK0UGNUSU6JUlXS
UACC-257	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2DncGlEPTB;Nz6wOFUyOiEQvF2=	NHnGOmhUSU6JUlXS
KM-H2	NVS2WW5ZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NF\4cZNKSzVyPUeuNVg1PTdizszN	NUGxSFJoW0GQR2LFVi=>
NCI-H1436	MnryS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MX7JR\|UxRTdwNkm5N\|Ih\|ryP	M1fPXXNCVkeURWK=
IA-LM	NXHIbpduT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVHBR41CUUN3ME23Mlg2QSEQvF2=	MYHTRW5IWkWU
NCI-H526	Mn7IS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3\F[WlEPTB;OD6yOVY{PyEQvF2=	NX3pOlF6W0GQR2LFVi=>
GCIY	NWfBe\|JQT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MUjJR\|UxRThwM{[5OlUh\|ryP	NYO1cIppW0GQR2LFVi=>
CP67-MEL	NH\LcY5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2nKSWlEPTB;OD61N\|I3KM7:TR?=	M3TJSnNCVkeURWK=
KALS-1	M{WwZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NF75d2JKSzVyPUiuPFM5PTFizszN	M{fHN3NCVkeURWK=
NCI-H1770	MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MWTJR\|UxRThwOUCyOlUh\|ryP	M2XsdHNCVkeURWK=
8-MG-BA	MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MojkTWM2OD17LkOyPFQ1KM7:TR?=	MoHoV2FPT1KHUh?=
KY821	NVTrZ5diT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4fGSmlEPTB;OT63O\|Q5PCEQvF2=	NUjGSmd3W0GQR2LFVi=>
SNB75	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVHJR\|UxRTFyLkC3OkDPxE1?	M2DIb3NCVkeURWK=
NCCIT	NEn2NZVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NF;1[pBKSzVyPUGxMlA2QDJizszN	NGfFTXdUSU6JUlXS
SJSA-1	NV;xe4M6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NV\jNlhZUUN3ME2xNU4zQDlzIN88US=>	NHrIVYRUSU6JUlXS
LB373-MEL-D	M1LGe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXHJR\|UxRTFzLkO4Nlch\|ryP	NUjRXlh[W0GQR2LFVi=>
TALL-1	NYnaPGt{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnH2TWM2OD1zMT60NFU5KM7:TR?=	NFm3WHJUSU6JUlXS
NB69	M4W3eGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGLEcYpKSzVyPUGxMlc4ODVizszN	MnjWV2FPT1KHUh?=
NCI-H1355	NFvYc4lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MomyTWM2OD1zMT65OFI3KM7:TR?=	MUPTRW5IWkWU
DMS-153	NWK4UYEzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mmn3TWM2OD1zMj6wOFI3KM7:TR?=	NX[wWW5[W0GQR2LFVi=>
OPM-2	M4\kNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGfNZoFKSzVyPUGyMlE2QTZizszN	MljKV2FPT1KHUh?=
NB1	NVrsOpZUT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NGH4bWRKSzVyPUGyMlI6KM7:TR?=	NHfxVVRUSU6JUlXS
A3-KAW	NYnOWHUxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NGLHRZRKSzVyPUGyMlMzOzZizszN	MmrmV2FPT1KHUh?=
NCI-H1882	Ml7zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGq4dJZKSzVyPUGyMlQxPjZizszN	MUPTRW5IWkWU
KG-1	MoHXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1:4UmlEPTB;MUKuOlU1PSEQvF2=	MVjTRW5IWkWU
LC4-1	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{f6VGlEPTB;MUKuO\|cxPiEQvF2=	NYXKPIwxW0GQR2LFVi=>
HCE-T	NXvwU4RnT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWDZNXc6UUN3ME2xN{4xODR7IN88US=>	MoDrV2FPT1KHUh?=
NEC8	NYK3SmlTT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYDJR\|UxRTF\|LkGwN\|gh\|ryP	M2e1[HNCVkeURWK=
IST-MEL1	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mn7pTWM2OD1zMz61O\|g5KM7:TR?=	NV3EZ\|FTW0GQR2LFVi=>
EW-3	NV3F[ox7T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NGfqNYFKSzVyPUGzMlc1ODJizszN	MXTTRW5IWkWU
CTB-1	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MnLSTWM2OD1zND6wN\|I6KM7:TR?=	MXnTRW5IWkWU
LS-123	NGPQUYZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NWjhfY9nUUN3ME2xOE4yPTh6IN88US=>	MU\TRW5IWkWU
NCI-H1417	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGniUpRKSzVyPUG0MlMxPTJizszN	NXPkZ2hOW0GQR2LFVi=>
MZ7-mel	NWrMbINDT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MmTQTWM2OD1zND60OFM{KM7:TR?=	NGXK[HNUSU6JUlXS
JiyoyeP-2003	NYq2dnRTT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NEnJ[llKSzVyPUG1MlY{OjZizszN	M2DrVnNCVkeURWK=
ES6	NFHK[4hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVLlcIRMUUN3ME2xOk4zOzZzIN88US=>	Ml:5V2FPT1KHUh?=
HH	M2nnNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MoTCTWM2OD1zNz6xPVY{KM7:TR?=	NVLa[Y5UW0GQR2LFVi=>
SF539	NGq3NmNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFX3[HpKSzVyPUG3Mlk6OjJizszN	NEmyTmNUSU6JUlXS
Calu-6	NFyyfoVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXX0WopUUUN3ME2xPU4zOzlizszN	M1fuNXNCVkeURWK=
SK-MM-2	MmL5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWHJR\|UxRTF7LkW1OUDPxE1?	NFq0UpJUSU6JUlXS
IST-MES1	NFzvOVRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MnzjTWM2OD1zOT62OlY{KM7:TR?=	NEnjfmhUSU6JUlXS
GI-ME-N	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVLJR\|UxRTF7LkiyNlch\|ryP	M2nmcXNCVkeURWK=
CAL-148	M2HIS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M{nQNGlEPTB;MkCuPVk{PCEQvF2=	NF7PeGpUSU6JUlXS
EVSA-T	MmLpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MorTTWM2OD1{MT6xOFk6KM7:TR?=	NEP2eJNUSU6JUlXS
LP-1	MkixS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3faRmlEPTB;MkGuN\|Q{OiEQvF2=	M{XEeHNCVkeURWK=
BOKU	M1rke2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MoLlTWM2OD1{MT60OVM{KM7:TR?=	MX3TRW5IWkWU
KLE	Mn3FS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MU\JR\|UxRTJ{LkG5NFMh\|ryP	MnnBV2FPT1KHUh?=
LB831-BLC	NYnnTWd{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NI\kfoRKSzVyPUK1MlE2OjZizszN	NXf5dlJLW0GQR2LFVi=>
NCI-H889	NEXCZYhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHfJZ\|RKSzVyPUK1MlE6OzFizszN	MVjTRW5IWkWU
REH	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NX7z[pE3UUN3ME2yOU41PjdzIN88US=>	M4TyVHNCVkeURWK=
KP-N-RT-BM-1	MkS3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWPJR\|UxRTJ3LkS3OVIh\|ryP	NHfEW\|FUSU6JUlXS
MPP-89	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NWfN[VFvUUN3ME2yOU42OzF2IN88US=>	NY\xRol5W0GQR2LFVi=>
no-11	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4HPZWlEPTB;MkWuO\|Q4KM7:TR?=	NUf1PWFqW0GQR2LFVi=>
NCI-H748	NFTWflZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXXIT3dPUUN3ME2yOU44PjJ5IN88US=>	NGfaRpJUSU6JUlXS
LB2518-MEL	NEfEeIhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NGnBZpdKSzVyPUK3MlE4PzNizszN	NWHi[pVlW0GQR2LFVi=>
TGBC1TKB	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYDhR3RtUUN3ME2yO{42PTh3IN88US=>	NVuwWYxsW0GQR2LFVi=>
MHH-PREB-1	M4TiUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1TZdWlEPTB;MkiuNFc{PCEQvF2=	M{jt[XNCVkeURWK=
MZ2-MEL	NGfIZ4pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFnnT5JKSzVyPUK4MlYyPDNizszN	MVnTRW5IWkWU
U-266	NHXhO4tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWnJR\|UxRTJ6Lk[zOlYh\|ryP	MVzTRW5IWkWU
SNU-C1	M{fxUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1TTSmlEPTB;MkiuPVQ{KM7:TR?=	NYS1dVlwW0GQR2LFVi=>
SW962	NVz0O41TT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NIm0TmtKSzVyPUOwMlI4PDdizszN	MmnwV2FPT1KHUh?=
Raji	M2DjSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mn3BTWM2OD1\|MD61OVkzKM7:TR?=	NWO0fYxYW0GQR2LFVi=>
KNS-42	MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2HxOWlEPTB;M{CuPFk2PiEQvF2=	NVq1dVBXW0GQR2LFVi=>
LB996-RCC	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MoXJTWM2OD1\|MT6xO\|AzKM7:TR?=	MXnTRW5IWkWU
CHP-126	MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MmLzTWM2OD1\|MT6xPVg1KM7:TR?=	NXO3VoN4W0GQR2LFVi=>
RXF393	NGLKT4tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MoLPTWM2OD1\|Mj60PVch\|ryP	NXL4WYdzW0GQR2LFVi=>
COLO-684	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Ml3NTWM2OD1\|Mj62OFM5KM7:TR?=	M3PofHNCVkeURWK=
A704	MmHhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{nTemlEPTB;M{OuOVU{QCEQvF2=	M2XhbXNCVkeURWK=
A253	Mk\zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXXWVXFHUUN3ME2zN{42QDV{IN88US=>	NWq1dYk2W0GQR2LFVi=>
KNS-81-FD	NY\jNJVxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M37sV2lEPTB;M{SuOVQ2PiEQvF2=	Ml3qV2FPT1KHUh?=
TE-441-T	NWSydnlmT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MkDMTWM2OD1\|ND62N\|cyKM7:TR?=	NWraVnRoW0GQR2LFVi=>
HCC2157	Mlj4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4nXR2lEPTB;M{WuOFYyQSEQvF2=	M{fKbHNCVkeURWK=
ES3	NELIU2ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MlXFTWM2OD1\|Nj62O\|Uh\|ryP	MnzWV2FPT1KHUh?=
NCI-H1155	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYfJR\|UxRTN5LkixOUDPxE1?	NUP0XZpuW0GQR2LFVi=>
SNU-C2B	M4fzfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHzaUWlKSzVyPUO4MlE3PTRizszN	MX\TRW5IWkWU
JAR	NUXGdFhvT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MlrrTWM2OD1\|OD6yOFQ6KM7:TR?=	NIPyc29USU6JUlXS
GDM-1	M{C0XWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MmfjTWM2OD1\|OD65NVE3KM7:TR?=	Mor6V2FPT1KHUh?=
KU812	M2DXXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWGzbnFkUUN3ME20NU42ODdizszN	MW\TRW5IWkWU
BC-1	M135Umdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3frbGlEPTB;NEKuOlc{OSEQvF2=	NWfpZ4pSW0GQR2LFVi=>
GI-1	NWPiVIdYT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVPBbmNDUUN3ME20Nk46OTl{IN88US=>	Mlq2V2FPT1KHUh?=
NCI-H1694	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYHJR\|UxRTR2Lkm0O\|Ih\|ryP	MYXTRW5IWkWU
DG-75	M1rYZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NX3vVFJlUUN3ME20OU4yPTd5IN88US=>	M{nkTnNCVkeURWK=
COR-L88	NFXvWZFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MoH0TWM2OD12NT6yO\|c5KM7:TR?=	MYnTRW5IWkWU
LS-513	M2HCWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NUjSWG1[UUN3ME20OU46OTV4IN88US=>	NHvpdVNUSU6JUlXS
HD-MY-Z	M4DkPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXzYbZB2UUN3ME20Ok41PjF{IN88US=>	NX\LNmNGW0GQR2LFVi=>
L-363	M1\Xb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NV72Z2pTUUN3ME20Ok45QDFizszN	MYHTRW5IWkWU
TE-6	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYjPTmw4UUN3ME20PE41PDZizszN	MVfTRW5IWkWU
NCI-H345	MkHMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MkXwTWM2OD12OD60Olgh\|ryP	M4DBXXNCVkeURWK=
TE-5	NV3ycVRGT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVfIUopZUUN3ME20PU44OTF6IN88US=>	NF7QWJFUSU6JUlXS

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	DLK / p-MKK7 / MKK7 / p-JNK / JNK ; PubMed: 23431148 Proc Natl Acad Sci U S A Western blot of the DLK pathway members in RGCs (retinal ganglion cells) 4 h after immunopanning in the presence of 0, 0.03, 0.06, 0.125, 0.25, 0.5, 1, or 2 μM tozasertib. p-AURKA / AURKA / Survivin ; PubMed: 28218735 Oncogenesis BGC823 cells were incubated with indicated doses of VX-680 for 24 h before subjected to western blotting with the indicated antibodies. Densitometry was used to quantify the Survivin and GAPDH levels. The relative expression shown (right panel) are means±s.e.m. of the ratios of Survivin to GAPDH. YAP; PubMed: 31160567 Cell Death Dis Western blot analysis of YAP protein level in A549 cells treated with indicated doses of VX-680 for 24 h. p-AKT / p-GSK3β / Cleaved caspase-3 / Cleaved PARP ; PubMed: 21600017 J Transl Med NB4-R2 cells were collected, lysed and subjected to Western blot analysis with cleaved caspase-3, cleaved-PARP, pAkt-1 (Ser473), pGSK-3β (Ser9) specific antibodies. GAPDH was used as a loading control. Data shown is a representative of three independent experiments.	23431148 28218735 31160567 21600017
Immunofluorescence	α-tubulin / Aurora-A ; PubMed: 21600017 J Transl Med The morphology of mitotic spindle was shown by immunofluorescence staining with anti-α-tubulin antibody and anti-Aur-A antibodies. Microtubules were stained as green, Aur-A protein as red, and nucleus as blue.	21600017
Growth inhibition assay	Cell viability; PubMed: 21600017 J Transl Med VX-680 significantly suppresses the proliferation in a number of leukemic cell types. OCI-AML3, NB4, HL-60 and ML-1 cells were incubated with increasing doses of VX-680 (1, 2, 5 and 10 nM) for 24 hr. Cell viability was measured by MTT assay. Data summarized three independent experiments, p < 0.05, *p < 0.01, compared to control.	21600017

In vivo

VX-680 gives rise to a marked decrease in tumor size in a human AML (HL-60) xenograft model. In mude mice treateed with VX-680 at 75 mg/kg, twice a day intraperitoneally (b.i.d. i.p.) for 13 days, mean tumor volumes are reduced by 98%. Tumor growth decrease is dose dependent and significant at a dose of 12.5 mg/kg b.i.d. VX-680 is well tolerated, with a small decrease in body weight observed only at the highest dose. VX-680 also triggers tumor regresson in pancreatic and colon xenograft models. VX-680 also displays potent antitumor activity when infused i.v. in mude rats bearing established HCT116 tumors. A higher dose of VX-680 (2 mg/kg/h) improves efficacy with a 56% decrease in mean tumor volume. ^[1]

Protocol

Kinase Assay: ^[3]	- Collapse Kinase inhibition assays: The consumption of ATP is coupled via the pyruvate kinase/lactic dehydrogenase enzyme pair to the oxidation of NADH, which can be monitored through the decrease in absorption at 340 nm. Reactions contains 100 mM Tris (pH 8), 10 mM MgCl₂, 2.2 mM ATP, 1 mM phosphoenolpyruvate, 0.6 mg/mL NADH, 75 units/mL pyruvate kinase, 105 units/mL lactate dehydrogenase, and 0.5 mM substrate peptide (sequence: EAIYAAPFAKKK). Reactions (75 μL) are started by adding sufficient kinase to bring the reactions to 30 nM kinase concentration and the decrease in absorbance is monitored over 30 minutes at 30°C in a microtiter plate spectrophotometer. Inhibitory constants are obtained through addition of 3.75 μL VX-680 in 100% DMSO or DMSO alone. Ki values are calculated as follows, K _i = IC50 / (1 + [S]/K_d), where [S] = [ATP] = 2.2 mM, and K_d (of ATP to Abl) = 70 μM. These values are calculated assuming a K_d (ATP) of 70 μM for wild type and H396P Abl kinase domain.
Cell Research: ^[2]	- Collapse Cell lines: CAL-62 cells Concentrations: 5-500 nM Incubation Time: 4 days Method: The CAL-62 cells are cultured in the absence (dimethyl sulfoxide, DMSO) or the presence of 500 nM VX-680 for different periods of time (1-5 days). The dose-dependent effects of VX-680 on cell proliferation are evaluated by treating the different ATC cells for 4 days with different concentrations of the Aurora inhibitor (5–500 nM). The cells are pulse labeled with 30 mM BrdU for 2 hours before the end of the incubation time. The BrdU incorporation is analyzed by means of a colorimetric immunoassay using the cell proliferation ELISA kit. The results from VX-680-treated cells are compared with those observed in control cells and expressed as a fold of variation versus control. (Only for Reference)
Animal Research: ^[1]	- Collapse Animal Models: Female athymic NCr-nu mice bearing HL-60 leukemia cells Formulation: 50% PEG300 in 50 mM phosphate buffer Dosages: 50 mg/kg, 75 mg/kg Administration: Administered via i.p. (Only for Reference)

References

[4] Cheetham GM, et al. Cancer Lett. 2007, 251(2), 323-329.

- Collapse

Solubility (25°C)

In vitro	DMSO	93 mg/mL (200.17 mM)
	Water	Insoluble
	Ethanol	Insoluble
In vivo	Add solvents to the product individually and in order(Data is from Selleck tests instead of citations): 5% DMSO+30% PEG 300+2% Tween 80+ddH2O For best results, use promptly after mixing.	15mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download Tozasertib (VX-680, MK-0457) SDF

Molecular Weight	464.59
Formula	C₂₃H₂₈N₈OS
CAS No.	639089-54-6
Storage	3 years -20°C powder
Storage	2 years -80°C in solvent
Synonyms	N/A

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Aurora Kinase Signaling Pathway Map

Aurora Kinase Inhibitors with Unique Features

Pan Aurora Kinase Inhibitors

Danusertib (PHA-739358) : Pan-Aurora kinase inhibitor, Aurora A/B/C, IC50=13 nM/79 nM/61 nM.
Pan Aurora Kinase Inhibitors

SNS-314 Mesylate : Pan-Aurora kinase inhibitor, Aurora A/B/C, IC50=9 nM/31 nM/3 nM.
Most Potent Aurora Kinase Inhibitor

MK-5108 (VX-689) : Aurora A, IC50=0.064 nM.
Aurora Kinase Inhibitor in Clinical Trial

Alisertib (MLN8237) : Phase III for Relapsed/Refractory Peripheral T-Cell Lymphoma.
Classic Aurora Kinase Inhibitor

Hesperadin : Potently inhibits Aurora B with IC50 of 250 nM.

Related Aurora Kinase Products

Ro-3306 ^New

RO-3306 is an ATP-competitive, and selective CDK1 inhibitor with K_i of 20 nM, >15-fold selectivity against a diverse panel of human kinases.
CCG-1423 ^New

CCG-1423 is a specific RhoA pathway inhibitor, which inhibits SRF-mediated transcription.
ML141 ^New

ML141 (CID-2950007), is demonstrated to be a potent, selective and reversible non-competitive inhibitor of Cdc42 GTPase suitable for in vitro assays, with IC50 of 200 nM and selectivity against other members of the Rho family of GTPases (Rac1, Rab2, Rab7).
Alisertib (MLN8237)

Alisertib (MLN8237) is a selective Aurora A inhibitor with IC50 of 1.2 nM in a cell-free assay. It has >200-fold higher selectivity for Aurora A than Aurora B. Phase 3.

Features:First orally available inhibitor of Aurora A.
Barasertib (AZD1152-HQPA，AZD2811)

Barasertib (AZD1152-HQPA) is a highly selective Aurora B inhibitor with IC50 of 0.37 nM in a cell-free assay, ~3700 fold more selective for Aurora B over Aurora A. Phase 1.
Danusertib (PHA-739358)

Danusertib (PHA-739358) is an Aurora kinase inhibitor for Aurora A/B/C with IC50 of 13 nM/79 nM/61 nM in cell-free assays, modestly potent to Abl, TrkA, c-RET and FGFR1, and less potent to Lck, VEGFR2/3, c-Kit, CDK2, etc. Phase 2.
ZM 447439

ZM 447439 is a selective and ATP-competitive inhibitor for Aurora A and Aurora B with IC50 of 110 nM and 130 nM, respectively. It is more than 8-fold selective for Aurora A/B than MEK1, Src, Lck and has little effect against CDK1/2/4, Plk1, Chk1, etc.

Features:An Aurora selective ATP-competitive inhibitor.
MLN8054

MLN8054 is a potent and selective inhibitor of Aurora A with IC50 of 4 nM in Sf9 insect cell. It is more than 40-fold selective for Aurora A than Aurora B. Phase 1.
MK-5108 (VX-689)

MK-5108 (VX-689) is a highly selective Aurora A inhibitor with IC50 of 0.064 nM in a cell-free assay and is 220- and 190-fold more selective for Aurora A than Aurora B/C, while it inhibits TrkA with less than 100-fold selectivity. Phase 1.
Aurora A Inhibitor I (TC-S 7010)

Aurora A Inhibitor I is a novel, potent, and selective inhibitor of Aurora A with IC50 of 3.4 nM in a cell-free assay. It is 1000-fold more selective for Aurora A than Aurora B.

Features:Aurora A Inhibitor I is a novel, potent, and selective inhibitor to Aurora A.

Choose Your Country or Region

By Signaling Pathways

By product type

Tozasertib (VX-680, MK-0457)

Cited by 67 Publications

Purity & Quality Control

Choose Selective Aurora Kinase Inhibitors

Biological Activity

Protocol

References

Solubility (25°C)

Chemical Information Download Tozasertib (VX-680, MK-0457) SDF

Bio Calculators

Molarity Calculator

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

Dilution Calculator

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

The Serial Dilution Calculator Equation

Serial Dilutions

Computed Result

Molecular Weight Calculator

Total Molecular Weight: g/mol

Instructions to calculate molar mass (molecular weight) of a chemical compound:

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molarity Calculator

Tech Support

Aurora Kinase Signaling Pathway Map

Aurora Kinase Inhibitors with Unique Features

Related Aurora Kinase Products

Choose Your Country or Region

By Signaling Pathways

By product type

Tozasertib (VX-680, MK-0457)

Cited by 67 Publications

Purity & Quality Control

Choose Selective Aurora Kinase Inhibitors

Biological Activity

Protocol

References

Solubility (25°C)

Chemical Information Download Tozasertib (VX-680, MK-0457) SDF

Bio Calculators

Molarity Calculator

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

Dilution Calculator

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

The Serial Dilution Calculator Equation

Serial Dilutions

Computed Result

Molecular Weight Calculator

Total Molecular Weight: g/mol

Instructions to calculate molar mass (molecular weight) of a chemical compound:

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molarity Calculator

Tech Support

Aurora Kinase Signaling Pathway Map

Aurora Kinase Inhibitors with Unique Features

Related Aurora Kinase Products

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)